Keyword: Repare Therapeutics
Repare Therapeutics plans to start testing ATR inhibitor RP-3500 in the clinic next year while putting a second asset through preclinical studies.
CRISPR has made it possible for Repare to increase both the scale and precision of the search for drug targets that can induce synthetic lethality in cancer cells.
The philosophy of Fierce 15 is a simple one: We want to see the best science combined with the brightest teams, and we want to see the promise that they hold in their hands has a genuine chance of being the Next Big Thing. Here are this year's standouts.